Abstract
Background Hyperinsulinemia, hyperglycemia, and obesity have been identified as risk factors for a variety of cancers [1]. Insulin inhibition (INSINH) can potentially limit cancer growth by factors including ketosis [2], and apoptosis secondary to fatty acid synthase inhibition [3] as well as intracellular potassium depletion [4]. Furthermore, dysregulation of many signaling proteins downstream of the insulin/IGF receptors such as PI3K/Akt, mTOR (inhibition) and AMPK (amplification) is a major area of drug target development [5,6]. We performed a four week INSINH diet in patients with advanced cancers to study safety/feasibility and also to examine a change inF-2-fluoro, 2-deoxyglucose (FDG) uptake on PET scan as a surrogate measure for tumor response.
Highlights
Hyperinsulinemia, hyperglycemia, and obesity have been identified as risk factors for a variety of cancers [1]
SD/PR correlated with three-fold higher ketosis compared to those with continued progressive disease (PD) (n=4), (p
Preliminary pilot data in ten subjects demonstrated that an Insulin inhibition (INSINH) diet is safe and feasible in selected patients with advanced cancer
Summary
Hyperinsulinemia, hyperglycemia, and obesity have been identified as risk factors for a variety of cancers [1]. Methods Eligible patients had failed or refused ≥2 standard chemotherapy courses. Exclusions included concurrent chemotherapy, end-organ disease, hypoglycemic medications, difficult compliance, or BMI < 20. A supervised INSINH diet restricted starches and sugars for 28 days, and was monitored weekly for macronutrient intake, body weight, [glucose] [BHB], [insulin], [IGF1,2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
